• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定 V6.51L 为立体选择性 A 腺苷受体拮抗剂识别的选择性热点。

Identification of V6.51L as a selectivity hotspot in stereoselective A adenosine receptor antagonist recognition.

机构信息

Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.

Department of Cell and Molecular Biology and Science for Life Laboratory, Uppsala University, Box 596, 751 24, Biomedical CenterUppsala, Sweden.

出版信息

Sci Rep. 2021 Jul 8;11(1):14171. doi: 10.1038/s41598-021-93419-x.

DOI:10.1038/s41598-021-93419-x
PMID:34238993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8266863/
Abstract

The four adenosine receptors (ARs) AAR, AAR, AAR and AAR are G protein-coupled receptors (GPCRs) for which an exceptional amount of experimental and structural data is available. Still, limited success has been achieved in getting new chemical modulators on the market. As such, there is a clear interest in the design of novel selective chemical entities for this family of receptors. In this work, we investigate the selective recognition of ISAM-140, a recently reported AAR reference antagonist. A combination of semipreparative chiral HPLC, circular dichroism and X-ray crystallography was used to separate and unequivocally assign the configuration of each enantiomer. Subsequently affinity evaluation for both A and A receptors demonstrate the stereospecific and selective recognition of (S)-ISAM140 to the AAR. The molecular modeling suggested that the structural determinants of this selectivity profile would be residue V250 in AAR, which is a leucine in all other ARs including the closely related AAR. This was herein confirmed by radioligand binding assays and rigorous free energy perturbation (FEP) calculations performed on the L249V mutant AAR receptor. Taken together, this study provides further insights in the binding mode of these AAR antagonists, paving the way for future ligand optimization.

摘要

四种腺苷受体(ARs)A1AR、A2AR、A2BAR 和 A3AR 是 G 蛋白偶联受体(GPCRs),已经有大量的实验和结构数据。然而,在将新的化学调节剂推向市场方面,取得的成功有限。因此,人们对设计这种受体家族的新型选择性化学实体有着明确的兴趣。在这项工作中,我们研究了最近报道的 A1AR 参考拮抗剂 ISAM-140 的选择性识别。使用半制备手性 HPLC、圆二色性和 X 射线晶体学的组合,对每个对映体进行分离和明确分配。随后对 A 和 A 受体的亲和力评估表明,(S)-ISAM140 对 A1AR 具有立体特异性和选择性识别。分子建模表明,这种选择性特征的结构决定因素将是 A1AR 中的残基 V250,而在包括密切相关的 A2AR 在内的所有其他 AR 中,该残基都是亮氨酸。这通过放射性配体结合测定和对 L249V 突变 A1AR 受体进行严格的自由能扰动(FEP)计算得到了证实。总之,这项研究为这些 A1AR 拮抗剂的结合模式提供了进一步的见解,为未来的配体优化铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/451b8dab4b55/41598_2021_93419_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/86aea9c2d718/41598_2021_93419_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/905c23fd1b77/41598_2021_93419_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/fa6eed66eb13/41598_2021_93419_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/3ddf24e02968/41598_2021_93419_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/37ca4b4dbbf5/41598_2021_93419_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/451b8dab4b55/41598_2021_93419_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/86aea9c2d718/41598_2021_93419_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/905c23fd1b77/41598_2021_93419_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/fa6eed66eb13/41598_2021_93419_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/3ddf24e02968/41598_2021_93419_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/37ca4b4dbbf5/41598_2021_93419_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3852/8266863/451b8dab4b55/41598_2021_93419_Fig6_HTML.jpg

相似文献

1
Identification of V6.51L as a selectivity hotspot in stereoselective A adenosine receptor antagonist recognition.鉴定 V6.51L 为立体选择性 A 腺苷受体拮抗剂识别的选择性热点。
Sci Rep. 2021 Jul 8;11(1):14171. doi: 10.1038/s41598-021-93419-x.
2
A and A adenosine receptors: The extracellular loop 2 determines high (A) or low affinity (A) for adenosine.A 和 A 腺苷受体:细胞外环 2 决定了对腺苷的高(A)或低亲和力(A)。
Biochem Pharmacol. 2020 Feb;172:113718. doi: 10.1016/j.bcp.2019.113718. Epub 2019 Nov 18.
3
The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors.GPCRs 的第二细胞外环决定了亚型选择性,并通过 A2 腺苷受体的环交换研究证明了其控制效力。
Biochem Pharmacol. 2013 May 1;85(9):1317-29. doi: 10.1016/j.bcp.2013.03.005. Epub 2013 Mar 13.
4
A adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models.腺嘌呤受体拮抗剂可挽救产生腺嘌呤的患者来源的癌症模型中的淋巴细胞活性。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004592.
5
Exploring Biginelli-based scaffolds as A adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents.探索基于 Biginelli 的支架作为 A 腺苷受体拮抗剂:揭示新的结构-活性关系趋势、先导化合物和有效的结直肠癌抗癌剂。
Biomed Pharmacother. 2024 Apr;173:116345. doi: 10.1016/j.biopha.2024.116345. Epub 2024 Mar 5.
6
Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors.基于结构的四个腺苷受体的有效和选择性配体的设计。
Molecules. 2017 Nov 10;22(11):1945. doi: 10.3390/molecules22111945.
7
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A Adenosine Receptor Antagonists.X 射线晶体学和自由能计算揭示了 A 腺苷受体拮抗剂的结合机制。
Angew Chem Int Ed Engl. 2020 Sep 14;59(38):16536-16543. doi: 10.1002/anie.202003788. Epub 2020 Jul 22.
8
Modafinil exerts anti-inflammatory and anti-fibrotic effects by upregulating adenosine A and A receptors.莫达非尼通过上调腺苷 A 和 A 受体发挥抗炎和抗纤维化作用。
Purinergic Signal. 2024 Aug;20(4):371-384. doi: 10.1007/s11302-023-09973-8. Epub 2023 Nov 8.
9
Activation of adenosine A or A receptors causes hypothermia in mice.腺苷 A 或 A 受体的激活会导致小鼠体温降低。
Neuropharmacology. 2018 Sep 1;139:268-278. doi: 10.1016/j.neuropharm.2018.02.035. Epub 2018 Mar 13.
10
Characterisation of endogenous A and A receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A-selective antagonist PSB 603.使用GloSensor™生物传感器对HEK 293细胞中内源性A和A受体介导的环磷酸腺苷反应进行表征:A选择性拮抗剂PSB 603变构作用机制的证据。
Biochem Pharmacol. 2018 Jan;147:55-66. doi: 10.1016/j.bcp.2017.10.013. Epub 2017 Oct 26.

引用本文的文献

1
Ligand and Residue Free Energy Perturbations Solve the Dual Binding Mode Proposal for an AAR Partial Agonist.配体和残基自由能扰动解决了AAR部分激动剂的双重结合模式问题。
J Phys Chem B. 2025 Jan 23;129(3):886-899. doi: 10.1021/acs.jpcb.4c07391. Epub 2025 Jan 8.
2
Structural insight into the dual-antagonistic mechanism of AB928 on adenosine A receptors.结构洞察 AB928 对腺苷 A 受体的双重拮抗作用机制。
Sci China Life Sci. 2024 May;67(5):986-995. doi: 10.1007/s11427-023-2459-8. Epub 2024 Jan 31.
3
Structural basis of selective cannabinoid CB receptor activation.

本文引用的文献

1
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A Adenosine Receptor Antagonists.氮漫步方法探索一系列强效 A 腺苷受体拮抗剂中的生物等排替换物。
J Med Chem. 2020 Jul 23;63(14):7721-7739. doi: 10.1021/acs.jmedchem.0c00564. Epub 2020 Jul 7.
2
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A Adenosine Receptor Antagonists.X 射线晶体学和自由能计算揭示了 A 腺苷受体拮抗剂的结合机制。
Angew Chem Int Ed Engl. 2020 Sep 14;59(38):16536-16543. doi: 10.1002/anie.202003788. Epub 2020 Jul 22.
3
Trifluorinated Pyrimidine-Based A Antagonists: Optimization and Evidence of Stereospecific Recognition.
选择性大麻素 CB 受体激活的结构基础。
Nat Commun. 2023 Mar 15;14(1):1447. doi: 10.1038/s41467-023-37112-9.
4
Cryo-EM structure of the human adenosine A receptor-G signaling complex.人源腺苷 A 受体-G 信号复合物的冷冻电镜结构。
Sci Adv. 2022 Dec 23;8(51):eadd3709. doi: 10.1126/sciadv.add3709.
5
Exploring the Effect of Halogenation in a Series of Potent and Selective A Adenosine Receptor Antagonists.探索一系列强效和选择性 A 腺苷受体拮抗剂中卤化的效果。
J Med Chem. 2023 Jan 12;66(1):890-912. doi: 10.1021/acs.jmedchem.2c01768. Epub 2022 Dec 14.
6
Molecular Simulations and Drug Discovery of Adenosine Receptors.腺苷受体的分子模拟与药物发现。
Molecules. 2022 Mar 22;27(7):2054. doi: 10.3390/molecules27072054.
7
Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A Receptor with Preladenant Conjugates.单一稳定点突变使阿腺苷受体与前洛丹文缀合物的高分辨率共晶结构成为可能。
Angew Chem Int Ed Engl. 2022 May 23;61(22):e202115545. doi: 10.1002/anie.202115545. Epub 2022 Mar 24.
三氟嘧啶基 A 拮抗剂:优化和立体特异性识别的证据。
J Med Chem. 2019 Oct 24;62(20):9315-9330. doi: 10.1021/acs.jmedchem.9b01340. Epub 2019 Oct 4.
4
QresFEP: An Automated Protocol for Free Energy Calculations of Protein Mutations in Q.QresFEP:一种用于 Q 中蛋白质突变自由能计算的自动化方案。
J Chem Theory Comput. 2019 Oct 8;15(10):5461-5473. doi: 10.1021/acs.jctc.9b00538. Epub 2019 Sep 4.
5
QligFEP: an automated workflow for small molecule free energy calculations in Q.QligFEP:用于Q中小分子自由能计算的自动化工作流程。
J Cheminform. 2019 Apr 2;11(1):26. doi: 10.1186/s13321-019-0348-5.
6
Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.腺苷受体突变的结构映射:配体结合和信号转导机制。
Trends Pharmacol Sci. 2018 Jan;39(1):75-89. doi: 10.1016/j.tips.2017.11.001. Epub 2017 Dec 5.
7
Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors.基于结构的四个腺苷受体的有效和选择性配体的设计。
Molecules. 2017 Nov 10;22(11):1945. doi: 10.3390/molecules22111945.
8
Structures of Human A and A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity.人 A 和 A 腺苷受体与黄嘌呤结构揭示了选择性的决定因素。
Structure. 2017 Aug 1;25(8):1275-1285.e4. doi: 10.1016/j.str.2017.06.012. Epub 2017 Jul 14.
9
Enantiospecific Recognition at the A Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates.烷基 2-氰基亚氨基-4-取代-6-甲基-1,2,3,4-四氢嘧啶-5-羧酸盐对 A 型腺苷受体的对映体特异性识别
J Med Chem. 2017 Apr 27;60(8):3372-3382. doi: 10.1021/acs.jmedchem.7b00138. Epub 2017 Apr 11.
10
A covalent antagonist for the human adenosine A receptor.一种针对人类腺苷A受体的共价拮抗剂。
Purinergic Signal. 2017 Jun;13(2):191-201. doi: 10.1007/s11302-016-9549-9. Epub 2016 Dec 3.